Payment overview · 2025
General Payments
$845.62
35 reported records · 16 companies
Healthcare provider profile · identity verified
Reyzan E Shali, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CARLSBAD, CA · NPI 1245245018
Verified facts
What the public records show
CMS Open Payments records show Reyzan E Shali, MD received $845.62 in general payments during 2025 across 35 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $237.12 | 28.0% | 12 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $112.94 | 13.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $84.32 | 10.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.77 | 9.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.50 | 7.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $47.66 | 5.6% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $34.70 | 4.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.93 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.22 | 3.3% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $22.66 | 2.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.64 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.16 | 2.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $17.18 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.49 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.83 | 1.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.50 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $845.62 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $206.06 | 10 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $112.94 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.77 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.77 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.82 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.17 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $34.70 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $34.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.90 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.15 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 109 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 155 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 127 |
| Losartan Potassium | Losartan Potassium | 304 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 80 |
| Lisinopril | Lisinopril | 220 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 189 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 56 |
| Potassium Chloride | Potassium Chloride | 131 | 50 |
| Famotidine | Famotidine | 126 | 34 |
| Memantine Hcl | Memantine Hcl | 116 | 23 |
| Eliquis | Apixaban | 109 | 31 |
| Gabapentin | Gabapentin | 109 | 30 |
| Metformin Hcl | Metformin Hcl | 108 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 37 |
| Furosemide | Furosemide | 104 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 33 |
| Atenolol | Atenolol | 94 | 28 |
| Trazodone Hcl | Trazodone Hcl | 92 | 27 |
| Omeprazole | Omeprazole | 89 | 32 |
| Alendronate Sodium | Alendronate Sodium | 88 | 24 |
| Carvedilol | Carvedilol | 80 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 17 |
| Donepezil Hcl | Donepezil Hcl | 72 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 16 |
| Sertraline Hcl | Sertraline Hcl | 67 | 21 |
| Alprazolam | Alprazolam | 65 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 37 |
| Simvastatin | Simvastatin | 59 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 34 |
| Valsartan | Valsartan | 52 | suppressed |
| Finasteride | Finasteride | 49 | 12 |
| Tramadol Hcl | Tramadol Hcl | 49 | 15 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | 16 |
| Meloxicam | Meloxicam | 45 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 14 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 32 |
| Nystatin | Nystatin | 40 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 15 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 15 |
| Baclofen | Baclofen | 37 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | 13 |
| Azithromycin | Azithromycin | 35 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 20 |
| Prednisone | Prednisone | 34 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | 11 |
| Estradiol | Estradiol | 32 | 13 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 12 |
| Mirtazapine | Mirtazapine | 30 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 23 |
| Acyclovir | Acyclovir | 29 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Ibandronate Sodium | Ibandronate Sodium | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | 11 |
| Metformin Hcl Er | Metformin Hcl | 25 | 11 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 15 |
| Lidocaine | Lidocaine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $845.62 · 35 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AMVUTTRA, AREXVY, AUSTEDO XR, BREZTRI, CAPVAXIVE, COLLAGENASE SANTYL, ELIQUIS, FREESTYLE LIBRE 3, Flexitouch Plus, GARDASIL 9, Nimbl, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, WaveWriter Alpha Prime 16, Wegovy, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error